Hydroxyzine imine is not a marketed, prescription‑only product that you’ll see on a pharmacy shelf. Instead, it’s an intermediate or metabolite that appears during hydroxyzine synthesis or metabolism. Because of that, there isn’t an “end‑user” market for hydroxyzine imine in the same way there is for hydroxyzine HCl (the drug you take for anxiety, itch, or pre‑operative sedation).
1. What is hydroxyzine imine?
- Chemical identity: C₁₉H₂₃NO₂, often written as hydroxyzine imine or hydroxyzine N‑oxide.
- Role in pharma:
- Synthesis intermediate – Some manufacturing routes generate the imine transiently before hydrolysis to the final drug (hydroxyzine HCl).
- Metabolite – After oral absorption, hydroxyzine is metabolized (primarily via CYP3A4) to a number of hydroxylated and imine‑type compounds that are excreted in urine.
- Regulatory status: Not registered as a therapeutic agent; therefore, it’s not subject to drug‑approval processes (FDA, EMA, etc.).
2. Why there’s essentially no commercial market for the imine
| Factor |
Explanation |
| No therapeutic claim |
The imine itself has no recognized pharmacologic activity in humans. |
| Short half‑life |
If present in the body, it’s quickly hydrolyzed or excreted. |
| Safety concerns |
Imine functionalities can be reactive; they’re generally avoided in final products. |
| Manufacturing context |
It’s a process chemical, not a finished dosage form. |
Because of these reasons, you will not find a market‑report, sales data, or a branded product listing for hydroxyzine imine. The “market” is essentially confined to:
- Pharmaceutical manufacturing – Companies that produce hydroxyzine may monitor the imine as a process control variable.
- Academic / research labs – In studies of metabolism or synthetic chemistry, the imine may be isolated and quantified.
3. The hydroxyzine market (for context)
Even though the imine itself isn’t marketed, hydroxyzine (the drug) is a well‑established antihistamine and anxiolytic. Here are some high‑level figures (all approximate, 2023‑2025 data):
| Segment |
Size / Share (USD) |
| Global antihistamine market |
~ $12–$15 billion annually (2023) |
| Hydroxyzine share |
0.5–1 % of the antihistamine segment (~ $70–$120 million per year) |
| Major manufacturers |
Pfizer, Mylan (now part of Viatris), GSK, and generic suppliers in India, China, and Latin America |
| Typical retail price |
$10–$40 per 25 mg capsule in the U.S. (varies by brand & pharmacy) |
Note: These numbers reflect hydroxyzine HCl (brand names include Atarax®, Vistaril®), not hydroxyzine imine.
4. Bottom line
- Hydroxyzine imine has no standalone commercial market.
- It’s a process‑specific intermediate or metabolite that is monitored in production or research, not sold as a drug.
- If you’re looking into hydroxyzine sales, pricing, or distribution, you’ll want to focus on hydroxyzine HCl, the actual medication.
5. Quick FAQ
| Question |
Answer |
| Can I buy hydroxyzine imine as a supplement? |
No; it is not sold to consumers and has no therapeutic claims. |
| Is it regulated under FDA? |
Only the final drug product (hydroxyzine HCl) is regulated; the imine is a process compound. |
| Do I need to report it to the DEA? |
No; it’s not a controlled substance. |
| Could it be used as an investigational drug? |
Only in very niche research settings; it’s not an approved investigational new drug (IND). |
If you’re interested in the pharmaceutical production side (e.g., synthesis routes, yields, regulatory aspects), let me know and I can dive deeper into the chemistry and quality‑control aspects. Otherwise, for market sizing and consumer pricing, the numbers above should give you a solid frame of reference.